Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Paxlovid  COVID-19 treatment studies for Paxlovid  C19 studies: Paxlovid  Paxlovid   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent: 
0 0.5 1 1.5 2+ Recovery time 15% Improvement Relative Risk Time to viral- 16% Time to viral- (b) 16% c19early.org/pl Zhong et al. ChiCTR2200060700 Paxlovid EARLY TREATMENT Favors paxlovid Favors control
The efficacy of paxlovid in elderly patients infected with SARS-CoV-2 omicron variants: Results of a non-randomized clinical trial
Zhong et al., Frontiers in Medicine, doi:10.3389/fmed.2022.980002, ChiCTR2200060700
6 Sep 2022    Source   PDF   Share   Tweet
Retrospective 106 paxlovid and 36 control patients in China, showing faster viral clearance with treatment.
recovery time, 14.7% lower, relative time 0.85, p = 0.26, treatment mean 4.81 (±3.0) n=106, control mean 5.64 (±2.87) n=36.
time to viral-, 15.8% lower, relative time 0.84, p = 0.009, treatment mean 7.51 (±2.79) n=106, control mean 8.92 (±2.61) n=36, viral shedding after enrollment.
time to viral-, 16.1% lower, relative time 0.84, p = 0.001, treatment mean 9.32 (±2.78) n=106, control mean 11.11 (±2.67) n=36, first positive to first of two negative tests.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Zhong et al., 6 Sep 2022, retrospective, China, peer-reviewed, 12 authors, study period 24 April, 2022 - 28 May, 2022, trial ChiCTR2200060700.
Contact: snailliyi@163.com, zhangwench88@hotmail.com, zhuchuanlong@jsph.org.cn.
All Studies   All Outcomes   Submit Updates or Corrections
This PaperPaxlovidAll
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit